Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Aytu Biopharma (AYTU) over the last 10 years, with Q4 2025 value amounting to $138042.0.

  • Aytu Biopharma's Non-cash Items rose 6958.68% to $138042.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $138042.0, marking a year-over-year increase of 6958.68%. This contributed to the annual value of $100195.0 for FY2025, which is 4990.25% down from last year.
  • Per Aytu Biopharma's latest filing, its Non-cash Items stood at $138042.0 for Q4 2025, which was up 6958.68% from $103898.0 recorded in Q3 2025.
  • Aytu Biopharma's Non-cash Items' 5-year high stood at $300000.0 during Q3 2021, with a 5-year trough of $2664.0 in Q4 2022.
  • Moreover, its 5-year median value for Non-cash Items was $96712.5 (2022), whereas its average is $110128.2.
  • Over the last 5 years, Aytu Biopharma's Non-cash Items had its largest YoY gain of 87233.7% in 2022, and its largest YoY loss of 9443.12% in 2022.
  • Quarter analysis of 5 years shows Aytu Biopharma's Non-cash Items stood at $47838.0 in 2021, then crashed by 94.43% to $2664.0 in 2022, then skyrocketed by 668.39% to $20470.0 in 2023, then surged by 297.65% to $81399.0 in 2024, then skyrocketed by 69.59% to $138042.0 in 2025.
  • Its Non-cash Items was $138042.0 in Q4 2025, compared to $103898.0 in Q3 2025 and $100195.0 in Q2 2025.